Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Commentary|Slideshows|November 15, 2024
Risk Factors for Type 1 Diabetes: A Snapshot for Primary Care
Author(s)Grace Halsey
About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.
Advertisement
Routine screening for type 1 diabetes in the general population is not currently recommended due to its relatively low prevalence. However, screening is strongly advised for high-risk populations—those with a family history of T1D or certain genetic markers associated with increased risk.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
Advertisement
Advertisement
Trending on Patient Care Online
1
New Schizophrenia Treatment Addresses Long-Standing LAI Barriers
2
New Study Finds Low Initiation, Persistence With Menopause Hormone Therapy
3
Primary Care Lens: Atrial Fibrillation From Detection to Referral in Primary Care
4
Elinzanetant Reduced Menopausal VMS Frequency by ≥50% in 67% of Women at Week 12: TMS 2026
5